Related Experiment Video
Updated: Jul 27, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled
1Kaiser-Permanente Medical Center, Los Angeles, California, USA.
American Journal of Clinical Oncology
|December 18, 1998
Summary
Patients with poorly controlled diabetes face increased risk of severe toxicity from 5-fluorouracil chemotherapy. Hyperglycemia directly correlates with toxicity levels, potentially leading to fatal outcomes.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- 5-fluorouracil (5-FU) is a common chemotherapy agent.
- Diabetes mellitus is a metabolic disorder characterized by hyperglycemia.
- The interaction between hyperglycemia and 5-FU toxicity is not fully understood.
Observation:
- Seven patients with diabetes receiving 5-FU experienced toxicity.
- Toxicity severity correlated directly with the degree of hyperglycemia.
- Two of three patients with severe hyperglycemia died from overwhelming toxicity.
Findings:
- Poorly controlled diabetes significantly increases the risk of severe 5-fluorouracil toxicity.
- In vitro studies from the 1960s demonstrated that glucose enhances 5-FU cytotoxicity.
- Hyperglycemia is a critical factor in 5-FU-related adverse events.
Implications:
- Caution is warranted when administering 5-fluorouracil to diabetic patients.
- Revised drug labeling should highlight the risks associated with hyperglycemia.
- Further research into managing 5-FU toxicity in diabetic patients is recommended.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:22Complications of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...